{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:08:35Z","timestamp":1780762115219,"version":"3.54.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.clindermatol.2012.08.013","type":"journal-article","created":{"date-parts":[[2013,2,21]],"date-time":"2013-02-21T21:20:08Z","timestamp":1361481608000},"page":"200-208","source":"Crossref","is-referenced-by-count":24,"title":["Targeted therapy in melanoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Ragini R.","family":"Kudchadkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiran S.M.","family":"Smalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Frank","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Trimble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2012.08.013_bb0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0010","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.hoc.2009.04.001","article-title":"BRAF signaling and targeted therapies in melanoma","volume":"23","author":"Dhomen","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0020","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0030","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1126\/science.1127515","article-title":"MC1R germline variants confer risk for BRAF-mutant melanoma","volume":"313","author":"Landi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0035","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1371\/journal.pmed.0050120","article-title":"Improving melanoma classification by integrating genetic and morphologic features","volume":"5","author":"Viros","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0040","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/1541-7786.MCR-06-0077","article-title":"Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression","volume":"4","author":"Kono","year":"2006","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0050","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0055","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd3463","article-title":"Ipilimumab","volume":"10","author":"Sondak","year":"2011","journal-title":"Nat Rev Drug Disc"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0060","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJMc1114329","article-title":"Vermurafenib sensitivity skin reaction after ipilimumab","volume":"366","author":"Harding","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0065","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0070","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-04-2423","article-title":"Mutant V599E B-Raf regulates growth and vascular development of malignant melanoma tumors","volume":"65","author":"Sharma","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0075","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0080","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0085","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"Bollag","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0090","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2010.28.15_suppl.8503","article-title":"Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors","volume":"28","author":"Kefford","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0095","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","article-title":"Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma","volume":"68","author":"Montagut","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0100","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy","volume":"102","author":"Paraiso","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1479-5876-8-67","article-title":"Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032","volume":"8","author":"Rubinstein","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0110","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1158\/1078-0432.CCR-07-1440","article-title":"The mitogen-activated protein\/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel","volume":"14","author":"Haass","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0120","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.bjc.6603596","article-title":"Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels","volume":"96","author":"Smalley","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0125","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1535-7163.MCT-06-0084","article-title":"Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases","volume":"5","author":"Smalley","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0130","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/sj.bjc.6603291","article-title":"Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis","volume":"95","author":"Eisen","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0135","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/1078-0432.CCR-08-2280","article-title":"Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib","volume":"15","author":"Jilaveanu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0140","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/sj.bjc.6605635","article-title":"Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT","volume":"102","author":"Handolias","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0145","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0150","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2011.00943.x","article-title":"Meeting report from the 2011 International Melanoma Congress, Tampa, Florida","volume":"25","author":"Smalley","year":"2012","journal-title":"Pigm Cell Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0155","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0160","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8502","article-title":"Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma","volume":"30","author":"Chapman","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0170","doi-asserted-by":"crossref","first-page":"CRA8503","DOI":"10.1200\/jco.2011.29.18_suppl.cra8503","article-title":"Phase I\/II study of the oral MEK1\/2 inhibitor GSK1120212 dosed in combination with the oral BRAF inhibitor GSK2118436","volume":"29","author":"Infante","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0175","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1158\/1078-0432.CCR-10-2200","article-title":"GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition","volume":"17","author":"Gilmartin","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0180","article-title":"A phase II study of the MEK1\/MEK2 inhibitor GSK21120212 in metastatic BRAF V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor","volume":"24","author":"Kim","year":"2011","journal-title":"Pigm Cell Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"New Engl J Med"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0190","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/onc.2011.250","article-title":"Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E) BRAF","volume":"31","author":"Xing","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0195","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-10-2954","article-title":"PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression","volume":"71","author":"Paraiso","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0200","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8501","article-title":"Tumor genetic analysis of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436","volume":"29","author":"Nathanson","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0205","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1158\/1535-7163.MCT-08-0431","article-title":"Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas","volume":"7","author":"Smalley","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0210","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/0008-5472.CAN-10-3761","article-title":"Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling","volume":"71","author":"Chen","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0215","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2011.05.015","article-title":"Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma","volume":"82","author":"Fedorenko","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0220","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/1078-0432.CCR-10-2225","article-title":"MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720","volume":"17","author":"Jiang","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0225","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1038\/onc.2011.424","article-title":"Adaptive upregulation of FOXD3 and resistance to PLX4032\/4720-induced cell death in mutant B-RAF melanoma cells","volume":"31","author":"Basile","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0230","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0235","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1126\/science.1179386","article-title":"Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma","volume":"326","author":"Yauch","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0240","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bcp.2010.04.006","article-title":"Targeted therapies of gastrointestinal stromal tumors (GIST)\u2014the next frontiers","volume":"80","author":"Duensing","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0245","first-page":"35","article-title":"Gatekeeper mutations mediate resistance to BRAF-targeted therapies","volume":"9","author":"Whittaker","year":"2010","journal-title":"Sci Trans Med"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0250","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0255","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0260","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0265","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0270","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/ncomms1727","article-title":"Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired BRAF inhibitor resistance","volume":"6","author":"Shi","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0275","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1078-0432.CCR-11-2612","article-title":"The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms","volume":"18","author":"Paraiso","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0280","article-title":"Phase I\/II expansion cohort of BRAF inhibitor GSK2118436 + MEK inhibitor GSK21120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAF inhibitor","volume":"24","author":"Flaherty","year":"2011","journal-title":"Pigm Cell Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0285","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8510","article-title":"Updated safety and efficacy results from a phase I\/II study of the oral BRAF inhibitor darbraenib (GSK2118436) combined with the oral MEK 1\/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0290","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.356","article-title":"Braf(V600E) cooperates with PTEN loss to induce metastatic melanoma","volume":"41","author":"Dankort","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0295","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0300","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1535-7163.MCT-09-0459","article-title":"Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates","volume":"8","author":"Woodman","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0305","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0310","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/cncr.21834","article-title":"Multi-center phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy","volume":"106","author":"Wyman","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0315","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/sj.bjc.6602529","article-title":"Lack of clinical efficacy of imatinib in metastatic melanoma","volume":"92","author":"Ugurel","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0320","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/311671a0","article-title":"A novel transforming gene in a human malignant melanoma cell line","volume":"311","author":"Padua","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0325","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.0022-202X.2004.22243.x","article-title":"Genetic interaction between NRAS and BRAF mutations and PTEN\/MMAC1 inactivation in melanoma","volume":"122","author":"Tsao","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0330","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0335","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0340","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/01.LAB.0000101732.89463.29","article-title":"Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanoma of the uvea","volume":"83","author":"Weber","year":"2003","journal-title":"Lab Invest"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0345","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic muations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0350","article-title":"The MEK inhibitor AZD244 (selumetinib) is active in GNAQ mutant ocular melanoma cells","author":"Ambrosini","year":"2010"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0355","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer","volume":"26","author":"Adjei","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0360","article-title":"AZD2444 (ARRY-142886) vs TMZ in patients with advanced melanoma: an open-labeled randomized, multicenter, phase II study","volume":"20","author":"Dummer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0365","first-page":"3660","article-title":"Disruption of the MMAC1\/PTEN gene by deletion or mutation is a frequent event in malignant melanoma","volume":"57","author":"Guldberg","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0370","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.3513","article-title":"A phase I study of XL281, a selective oral RAF kinase in patients with advanced solid tumors","volume":"27","author":"Schwartz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0375","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.seminoncol.2012.01.009","article-title":"Cutaneous toxicites of targeted therapies","volume":"39","author":"Robert","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0380","article-title":"Squamous cell tumors from RAF inhibitor treated patients have a distinct mutational profile supporting a mechanism of therapy induced tumorigenesis in Ras-primed cells","volume":"24","author":"Kee","year":"2011","journal-title":"Pigm Cell Melanoma Res"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0385","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"20","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0390","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0395","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0400","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0405","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2133.2009.09214.x","article-title":"Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors","volume":"161","author":"Osio","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0410","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0415","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaad.2006.10.032","article-title":"Keratoacanthomas associated with sorafenib therapy","volume":"56","author":"Kong","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0420","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0425","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000258880","article-title":"Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib","volume":"77","author":"Lipworth","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0430","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/107327480901600110","article-title":"Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene","volume":"16","author":"Marquez","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0435","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2009.02.004","article-title":"Array of cutaneous adverse effects associated with sorafenib","volume":"61","author":"Kong","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0440","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0445","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/annonc\/mdh068","article-title":"Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"15","author":"Arora","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0450","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.annder.2008.04.016","article-title":"Eruptive nevi associated with sorafenib treatment","volume":"135","author":"Bennani-Lahlou","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2012.08.013_bb0455","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1586\/era.11.30","article-title":"Identification of BRAF mutations in eruptive melanocytic envi: new insights into melanomagenesis?","volume":"11","author":"John","year":"2011","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X12001836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X12001836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T05:20:03Z","timestamp":1644384003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X12001836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0738081X12001836"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2012.08.013","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}